Articles tagged with Ovarian Cancer
Research on biodegradable nanomedicine shows promise in selectively destroying ovarian cancer cells left behind after surgery. The technology uses nanoparticles to provide real-time imaging and phototherapy treatment during surgery, achieving complete tumor eradication in mice with no adverse effects.
Researchers at the University of Georgia have discovered a mechanism that could lead to better ovarian cancer treatment by targeting chemoresistance. The RGS10 protein impacts the effectiveness of chemotherapy, and manipulating its expression can improve treatment outcomes.
PharmaMar presents new studies on the treatment of ovarian cancer using YONDELIS (trabectedin) and PM1183, showing promising results in managing recurrent cancer. The studies highlight the potential benefits of combining these therapies to improve patient outcomes.
Researchers found that mice with BRCA1 mutations exhibited enhanced responsiveness to male scent, which stimulated their estrous cycles and ovary function. This discovery suggests a potential indirect link between sense of smell and breast, ovarian cancer risk in women carrying BRCA1 mutations.
A Binghamton University biochemist has discovered a method to fight cancer by attacking only cancer cells and potentially reducing side effects. Hedgehogs, which normally turn off in mature cells, somehow re-activate in certain cancers, leading to uncontrolled cell growth.
A study of 41 Danish women who received ovarian tissue transplants found that the procedure is effective in restoring ovarian function and fertility in up to 10 years. The majority of patients (31%) became pregnant, with some even experiencing full-term pregnancies.
A study of commercially insured women found that most did not receive genetic counseling after BRCA testing, with lack of clinician recommendation being the main reason. Women who received counseling had greater knowledge and satisfaction with their test results.
Researchers developed a small array of flexible sensors to analyze breath samples for specific compounds indicative of ovarian cancer. The system showed an 82% accuracy rate in detecting these compounds, paving the way for a potential less invasive cancer diagnosis method.
A major clinical trial reports that hormone replacement therapy (HRT) is safe and may improve survival chances in women with epithelial ovarian cancer. The study followed 150 women with the common type of ovarian cancer and found that HRT did not reduce overall survival, but rather increased it.
Researchers found that adding hormonal treatment during chemotherapy reduced the risk of premature ovarian failure by 45% and increased pregnancy rates among young breast cancer patients. The use of LHRHa could be a potential standard strategy to preserve ovarian function and fertility in hormone receptor positive breast cancers.
Researchers at NC State University isolated possible ovarian cancer biomarkers using a highly sensitive mass spectrometry analysis. The study found that the level of biomarkers associated with ovarian cancer does not simply increase or decrease over the course of the disease, but can rise and fall during different stages.
Two studies suggest alternative prevention strategies may render surgery unnecessary for women at high risk of breast and ovarian cancer. Researchers identify a new target to decrease breast cancer risk by blocking the effects of RANKL with OPG.
Researchers found that generic heart medications, specifically nonselective beta-blockers, significantly improved overall survival among ovarian cancer patients. This is attributed to the ability of these drugs to block stress pathways involved in tumor growth and spread, with further research needed to explore their potential benefits.
A study found that multigene panel testing identified harmful mutations in moderate-risk genes and Lynch syndrome genes among 3.8% of women negative for BRCA1 and BRCA2 mutations. The test also recommended additional disease-specific screening and prevention measures for mutation-positive cases.
A study found that screening women with suspected hereditary breast or ovarian cancer risk for additional genes provides important information for changing clinical management. Most patients with identified mutations were recommended for enhanced screening or preventive measures, and close relatives should also be screened.
The University of South Florida (USF) and the cancer advocacy organization FORCE will advance a clinical research network focused on hereditary breast and ovarian cancer. The project aims to improve health outcomes for patients by leveraging large volumes of health data, enabling quicker and less expensive clinical research.
A UC Davis study found that nearly one-third of ovarian cancer patients survived at least 10 years after diagnosis, contradicting the common perception of poor survival rates. The research also identified younger, earlier-stage disease and lower-risk tumor types as factors associated with longer survival.
Researchers discovered that CA125-negative tumor cells have an enhanced ability to repair their DNA and resist programmed cell death, making them dangerous. Combining chemotherapy with birinapant significantly improved disease-free survival in laboratory models of human ovarian cancer.
A modified version of a protein that suppresses female reproductive organ development has been shown to inhibit the growth of chemotherapy-resistant ovarian tumors in animal models. Researchers at Massachusetts General Hospital have developed a gene therapy approach using a viral vector to deliver this protein, which resulted in signif...
Researchers at Lawson Health Research Institute have identified LKB1 as a key player in promoting and surviving ovarian cancer cells. This discovery contradicts previous studies, which suggested that LKB1 acts as a tumour suppressor in ovarian cancer.
Researchers have uncovered how key proteins can switch on RAD51, allowing it to repair cancer-causing DNA damage in cells. Women with faulty RAD51 and BRCA1 and BRCA2 genes are at higher risk of developing these cancers.
A new study found that longer periods of leisure time sitting were associated with a higher risk of total cancer risk in women, as well as increased risk of multiple myeloma, invasive breast cancer, and ovarian cancer. The association was not observed in men.
Researchers at Johns Hopkins have found that combining fostamatinib with paclitaxel can reduce tumor size in ovarian cancer cells by up to 87 percent. The combination therapy may provide a new treatment option for patients with recurrent advanced ovarian cancer who have developed resistance to standard treatments.
An international genome-wide association study (GWAS) has identified three genetic variants associated with mucinous ovarian carcinomas (MOCs), offering insights into the biology of this disease. The research also highlights the link between MOCs and colorectal cancer, as well as the discovery of a key gene called HOXD9.
Ovarian cancer suppresses immune cells' ability to respond to tumor cells by activating a gene called XBP1. A novel therapy approach aims to restore dendritic cell function and trigger robust immune responses against ovarian tumors.
A recent study reveals that nearly 1 in 3 counties in the US have limited access to specialty care for ovarian and cervical cancers, affecting 14.8 million women. The study also found that 15% of women may face barriers to care due to their referral network.
Researchers found that mutations in ARID1a gene sensitize certain tumors to PARP inhibitor drugs, allowing for more effective treatment options. The study highlights the importance of using genomic information to guide cancer therapy and identify precise treatments for individual patients.
Researchers discovered ovarian cancer cells can lock into survival mode and avoid chemotherapy destruction. The study, published in Nature, used whole genome sequencing to analyse tumour DNA samples from 91 patients with high-grade serous ovarian cancer.
Researchers at University of California, San Diego, have identified six mRNA isoforms that distinguish ovarian cancer cells from normal cells, offering potential for early diagnosis and targeted therapies. The study's findings may also lead to new therapeutic targets and more effective treatment options.
Researchers at MD Anderson Cancer Center have identified a biomarker that may boost the response to chemotherapy in patients with ovarian cancer. The study found that miR-506 was associated with improved responses to chemotherapy drugs cisplatin and olaparib, leading to better overall survival.
A Cancer Research UK study found that pre-surgery chemotherapy reduces side effects and hospital stays, leading to a better quality of life for patients. The trial challenged the international standard for treating advanced ovarian cancer.
PharmaMar presents clinical studies showcasing the efficacy of YONDELIS and PM1183 in treating small cell lung cancer, soft tissue sarcoma, and malignant pleural mesothelioma. The studies demonstrate promising results with a response rate of 67% for PM1183 in SCLC.
Myriad Genetics presented 19 clinical studies on advanced companion diagnostic and molecular diagnostic tests for cancer treatment and prevention. The company's research focuses on personalized medicine, including selecting effective pharmaceuticals, preventing disease through hereditary cancer tests, and optimizing treatment decisions...
A new screening method can detect twice as many women with ovarian cancer as conventional strategies, according to the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The method uses a statistical calculation to interpret changing CA125 levels in women's blood, providing a more accurate prediction of individual risk.
Researchers from MD Anderson Cancer Center are part of two new Stand Up to Cancer Dream Teams focused on lung cancer driven by KRAS mutations and preventing high-risk ovarian cancer. The teams aim to test combination therapies and launch prevention efforts.
A new ovarian cancer research team, funded by a $6 million grant, will focus on DNA repair therapies and prevention. The team aims to build on recent clinical advances with PARP inhibitors and develop a new web-based approach to genetic testing and counseling.
Researchers found that patients with anti-TP53 autoantibodies can detect ovarian cancer up to 13 months before rising CA125 levels. The study suggests a novel assay method for earlier detection of the disease.
A study has identified molecular changes that occur in tissue after chemotherapy in ovarian cancer patients. The researchers found that these changes could be potential targets for new, more personalized drugs. The findings have the potential to advance treatments for ovarian cancer.
Researchers successfully migrated immune cells to tumor sites in patients with mesothelin-expressing tumors. The treatment showed no major adverse events, suggesting patients tolerated it well, with T cells targeting and surviving at tumor sites for up to 28 days.
A recent study suggests that genetic testing for BRCA1 and BRCA2 mutations in women with ovarian cancer can help identify carriers and reduce their risk. The study found that 19% of women with the most common form of ovarian cancer carry these mutations, which is higher than previous estimates.
Researchers at the University of Utah Health have discovered patterns in DNA anomalies that predict a woman's outcome significantly better than tumor stage, also indicating how well she'll respond to platinum therapy. The new method could lead to personalized prognostic and diagnostic laboratory tests.
A study of over 31,000 women with BRCA1 and BRCA2 mutations found that the risk of breast and ovarian cancer varies by mutation type. The findings suggest that knowledge of mutation-specific risks could inform clinical decision-making among carriers.
Researchers found that specific BRCA mutations are linked to higher breast cancer risk and lower ovarian cancer risk, potentially leading to more personalized risk assessment and prevention strategies. The study analyzed data from over 31,000 women with BRCA1 or BRCA2 gene mutations.
A breakthrough discovery by Queen's University researcher Madhuri Koti has identified biomarkers that can predict the success of chemotherapy in ovarian cancer patients. This finding holds promise for improving treatment options and increasing patient survival rates.
A study published in Nature Structural & Molecular Biology reveals that human DNA polymerase theta may be a promising drug therapy target for inhibiting breast cancer. The researchers used X-ray crystallography to determine the first crystal structures of POLQ, providing insights into its role in DNA repair and genomic instability.
The Anderson Algorithm increases surgical success in advanced ovarian cancer by providing a personalized approach to surgery, resulting in high complete resection rates of over 86%. This milestone is strongly tied to improved survival outcomes for patients.
A Cancer Research UK study found that serous ovarian cancers with diverse genetic profiles are more likely to become resistant to chemotherapy and recur. This variability affects the prognosis of patients with these tumors, leading to earlier deaths compared to those with less varied tumors.
Researchers at The Wistar Institute have identified a new therapeutic target in ovarian clear cell carcinoma, a difficult-to-treat subtype of ovarian cancer. EZH2 inhibition causes regression of ovarian tumors with ARID1A mutation, providing a much-needed therapeutic strategy for clear cell ovarian cancer.
A meta-analysis of 52 studies found that short-term hormone replacement therapy (HRT) use is associated with a significantly increased risk of developing the two most common types of ovarian cancer. Women who used HRT for 5 years or more had a 40% higher likelihood of developing ovarian cancer compared to those who never took HRT.
Researchers at the University of Chicago Medical Center have created a new screening tool for ovarian cancer that can rapidly test compounds to block metastasis. The three-dimensional cell-culture system mimics human tissue and has identified small molecules that inhibit adhesion and invasion.
Researchers at Dartmouth have found that introducing a specific strain of bacteria into the microenvironment of ovarian cancer tumors can transform tumor cells from suppressors to attackers, sparking a strong anti-tumor immune response. The study's results demonstrate a new potential for treating various types of cancers.
Researchers discovered a new way to shrink ovarian cancer tumors by inhibiting abnormal angiogenesis. Using a naturally occurring protein inhibitor called 3TSR, the approach improved chemotherapy drug delivery and resulted in significant tumor regression and survival.
A team of UNC genetics researchers discovered how two genes interact to trigger cancer and spur its development. The research found that ARID1A and PIK3CA mutations led to the overproduction of Interleukin-6, a cytokine crucial for cell signaling that triggers inflammation.
A groundbreaking TGen-led discovery has identified the likely genetic cause of a rare form of ovarian cancer that affects young women and girls. The study found nearly universal underpinnings for this disease, which usually presents in advanced stages and is resistant to standard chemotherapy.
Researchers have found that loss of gene PTEN is a common driver event behind high-grade serous ovarian cancer, which is often fatal. Combining image analysis with genetic data helped identify PTEN levels in cancer cells while ignoring normal cells, paving the way for new treatments.
Researchers at MD Anderson Cancer Center discovered that targeting the non-coding microRNA miR569 can increase cell death in ovarian and breast cancers. The study also found that silencing miR569 expression improves survivability outcomes for ovarian patients.
A novel combination therapy using low-dose chemotherapy with an antiangiogenic treatment, 3TSR, improved survival rates in an animal model of ovarian cancer. The treatment resulted in tumor regression, improved blood flow, and more efficient delivery of chemotherapy drugs with reduced side effects.
Scientists have found a biological indicator that can predict which women without BRCA1/2 mutations will respond well to the PARP inhibitor rucaparib. The biomarker is related to genomic loss of heterozygosity, and its presence indicates that patients with ovarian cancers may benefit from treatment.
Researchers found that cirmtuzumab induces senescence in cancer stem cells, degrading their ability to grow and metastasize. Ovarian cancer patients with high levels of ROR1 experienced more aggressive forms of the disease, highlighting the potential of this antibody therapy as a targeted treatment.
Researchers at University of Guelph found a potential breakthrough in treating late-stage ovarian cancer by shrinking tumours and improving drug delivery. This approach may lead to novel treatment options with reduced morbidity and mortality.